Fortimedix Surgical develops a single-port surgery solution compatible with a standard 15mm trocar for minimally invasive abdominal laparoscopic procedures. Its lead product, the FMX314, received CE Mark approval and 510(k) clearance last quarter. The company plans a U.S. commercial launch of the FMX314 at the American College of Surgeons Clinical Congress (Oct 16–20, 2016) and a European commercial launch in 2017. Fortimedix will use the new funding to support the U.S. and European commercial launches. The company is led by CEO Wout Bijker and is based in Nuth, The Netherlands, with a subsidiary in San Diego. No operating metrics were disclosed in the article.

Total raised

$12M

Funding rounds

1

Latest round

Series A

Latest activity

Oct 2016